ST. PAUL, Minn. and NEW ORLEANS--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), announced data highlighting the advantages of its Diamondback and Predator 360® PAD Systems at the New Cardiovascular Horizons (NCVH) meeting in New Orleans. Both systems, developed by CSI, are minimally invasive catheter systems that remove hardened plaque to restore blood flow in peripheral arteries. Three different studies representing four e-abstracts confirm the safety and effectiveness, as well as long-term effectiveness of plaque modification with orbital technology in arteries above and below the knee. These studies contribute to a large and growing body of clinical evidence demonstrating that CSI’s orbital PAD systems can predictably treat peripheral arterial disease (PAD) in routine and complex cases.
